The expanding number of glucose-lowering interventionsfrom behavioural interventions to pharmacological interventions, devices and surgeryand growing information about their benefits and risks provide more options for people with diabetes and providers but complicate decision making
Recio-Iglesias J, Dez-Manglano J, Lpez-Garca F, Daz-Peromingo JA, Almagro P, Varela-Aguilar JM
FIGURE 4 Novel drug modalities for NRF2 activation Up to date, the only NRF2 activators in clinical use are DMF for MS (Rosito et al., 2020), and more recently Omaveloxolone, a semisynthetic terpenoid with potent NRF2-activating effects gained FDA approval in Februrary 2023 for the treatment of Friederichs ataxia ( However, most NRF2 activators are of electrophilic nature and exhibit unpredictable poly-pharmacology
That points less at the bone and more at staying steady on your feet
Just keep in mind that gaining more weight will cause fat to be stored in other areas of your body